Working hours... when nature calls ™

Preimplantation Genetic Diagnosis/Screening (PGD/PGS)

Preimplantation Genetic Diagnosis/Screening (PGD/PGS)

Preimplantation genetic diagnosis (PGD) involves the genetic testing of embryos followed by the selective transfer of genetically normal embryos.


PGD has also currently expanded to perform aneuploidy screening (preimplantation genetic screening - PGS). PGS is offered to couples with a high risk for a child with a genetic defect such as cases of advanced maternal age, repeated IVF failure, repeated miscarriage and non-obstructive azoospermia.


PGD/PGS can be offered for several genetic diseases and syndromes. Common genetic diseases that can be prevented through PGD/PGS include any chromosomal abnormalities (e.g. Down syndrome), thalassaemia, cystic fibrosis, fragile X syndrome, X-Linked disorders, e.t.c. In Cyprus, where the frequency of the individuals that carry the gene of b-thalassaemia is high in the population, PGD is of great importance.

 

Preimplantation Genetic Diagnosis involves the removal of a single blastomere from a day 3 cleavage embryo following its genetic testing. Blastomeres (single cells) are now analysed via a new molecular cytogenetic method called array-CGH that allows simultaneous analysis of the entire chromosome complement.

 

Blastocyst biopsy is an increasingly attractive alternative to day-3 biopsy. Blastocyst biopsy is only performed on high quality blastocysts that have had the opportunity to self-correct and undertook the first cellular differentiation. Blastocyst screening, however, is coupled to cryopreservation as it requires freezing of the blastocysts in order to allow array-CGH analysis.

Patient Testimonials

Combine Treatment with Leisure


|